Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48115 | 0.91 | SLC5A2 (0.40) | BCHEACHESLC5A2SLC5A1 | |
| SCHEMBL3684678 | 0.90 | SLC5A2 (0.43) | BCHEACHESLC5A2SLC5A1 | |
| SCHEMBL3679099 | 0.89 | BCHE (0.34) | BCHEACHESLC5A2SLC5A1 | |
| SCHEMBL13445717 | 0.83 | SLC5A2 (0.38) | BCHEACHESLC5A2SLC5A1 | |
| SCHEMBL25333903 | 0.82 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL18661895 | 0.82 | SLC5A2 (0.51) | SLC5A2SLC5A1 | |
| SCHEMBL13445807 | 0.81 | SLC5A2 (0.36) | BCHEACHESLC5A2SLC5A1 | |
| SCHEMBL12152975 | 0.80 | BCHE (0.44) | BCHEACHE | |
| SCHEMBL2578566 | 0.80 | BCHE (0.40) | BCHEACHESLC5A2 | |
| SCHEMBL2578567 | 0.80 | BCHE (0.40) | BCHEACHESLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2312944-B1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9061060-B2 | Deuterated benzylbenzene derivatives and methods of use | THERACOS INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063141-A1 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A1, SLC5A2, SLC2A4 | BCHE 1659/4885ACHE 4218/4885SLC5A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.